-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TJ-CD4B is an innovative bispecific antibody that simultaneously targets the tumor antigen claudin 18 splicing body 2 (Claudin 18.
Preclinical studies have shown that even in the case of low expression of Claudin 18.
This time, approved in the United States is a multi-center Phase 1 dose-climbing trial, which will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ-CD4B in patients with advanced or metastatic solid tumors.
Claudins are a family of proteins whose role is to maintain tight junctions that control the exchange of molecules between cells.
Claudin 18.
Current status of Claudin 18.
It is the highly selective expression of Claudin 18.
SPX-301 is a bispecific antibody drug developed by Sparx that simultaneously targets claudin18.
CLDN 18.